Please login to the form below

Not currently logged in
Email:
Password:

Nimbus looks to Merck for CEO

Donald Nicholson spent 26 years at US pharma giant

merck donald nicholsonNimbus has appointed Merck & Co's Donald Nicholson as the company's new CEO.

Nicholson spent 26 years at Merck holding various strategic leadership and operational roles in diverse therapeutic areas including respiratory inflammation immunology bone endocrine urology infectious diseases and neurosciences.

He began his career in 1988 at the Merck-Frost Centre for Therapeutic Research in Montreal.

In his new role at Nimbus Nicholson will lead a US biotech with a portfolio of programmes in immunology oncology and metabolic diseases targeting mechanisms that have been traditionally difficult or intractable. The company is expected to enter human clinical trials in early 2015.

It is thrilling to join the company at such a watershed moment as the lead programs move toward clinical development,” said Dr Nicholson. “I look forward to working with such a highly respected team of colleagues Board members and investors to deliver the greatest value of the portfolio to patients.”

1st October 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Stick or Twist? Healthcare brands in a (post) COVID-19 world
...
Stick or twist? Looking at the patient experience as we emerge from the COVID pandemic
...
Lockdown entertainment or healthcare revolution? The role of video games in healthcare
...